GAiT will be speaking at the 'Translation and Innovation in induced Pluripotent Stem Cell Science' Workshop at Saïd Business School, Oxford on the 11th February 2020 and at the RESTORE meeting in Berlin on the 17th February 2020.
Osaka University transplants iPS cell-based heart cells in world's first clinical trial
Osaka University transplants iPS cell-based heart cells in world's first clinical trial | The Japan Times
An Osaka University team said it has carried out the world's first transplant of cardiac muscle cells created from iPS cells in a physician-initiated ...
Who would have thought 5 years ago that GSK, BMS, Gilead, Pfizer, Roche, J&J, Takeda, Astellas, Vertex... - will become the major cell-gene therapy companies? The craze for acquisitions will continue in 2020. Pharma/Biotech will eat them all!
Thanks to all who participated in the iPSC Quality Round Data Discussion calls this week! Minutes will be sent out Monday.
A Quality Round update was just sent to Participants. We remind those doing retests to upload the data template sheets in addition to raw data.
Tokyo's Heartseed reaps $26M to test its iPS cell injections for heart failure - The company forms spherical clusters of heart cells from purified, allogeneic iPSCs, which are injected into the heart muscle wall.
We are very grateful for @NIBSC_MHRA, @MCRI_for_kids, @yposkesi, @nyscf, @Inserm, and @cmrb for joining the first two Quality Round data discussion calls today. Your comments and feedback have been documented.
GAiT just sent an iPSC Quality Round Update to Participants from 18 sites across 11 countries informing them of the status of Quality re-tests, the data workshop, and manuscript preparation.
Kyoto University seeks government approval to conduct a clinical trial of transplanted cartilage made from iPS cells -
Kyoto Univ. seeks to use stem cells for damaged knee joint treatment
Kyoto University says it has asked for government approval to conduct a clinical trial of transplanting cartilage made from induced pluripotent stem c...
We are looking for an associate scientist to work with #geneediting and #genomics on the NYSCF Global Stem Cell Array-- our automated system for #stemcell derivation, gene editing, and downstream differentiations. Learn more and apply here: http://bit.ly/33LS3Eg #STEMjobs
Do you want to #study & #work in the field of #RegenerativeMedicine? APPLY NOW to the
@wellcometrust funded "Advanced Therapies for Regenerative Medicine" course at the CSCRM
@KCLWP @KCLResDevHealth @kcldo1thing @kclwim @KCL_MRCDTP
GAiT's new Director Annelise Bennaceur Griscelli (@Inserm) will be attending the RESTORE meeting (Berlin) next week & will be discussing GAiT's efforts to standardize iPSC manufacture for allogeneic therapeutic development. More on RESTORE here: https://apnews.com/f9aca5d5fb2fa4100b29480d221e5658
If you are a Quality Round Participant and would like to discuss the Quality Round directly with GAiT before the planned conference calls, you can set up a direct meeting by emailing firstname.lastname@example.org
iPSC Quality Round 2019: material for secondary testing is being dispatched Monday 18th November 2019.
The key to the #commercialization journey is actually in developing relationships with stakeholders through an understanding of priorities, rather than trying to be an expert in all areas. #regenmed #commercialization @MTPConnect_AUS
It was useful to catch up with @BlueRockTx, @CGTCatapult and @CCRM_ca at the @ISSCR meeting in Toronto today. Three important participants in the iPSC #Quality Round 2019.
Fate Tx opens new GMP facility for iPSC therapeutic development
Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies | Fate Therapeutics, Inc.
The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial anal...
At the MARS Centre at the University of Toronto today, visiting @CCRM and holding discussions with other Canadian Participants of the iPSC Quality Round 2019 today and tomorrow.